Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial
Top Cited Papers
- 1 October 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in PAIN®
- Vol. 99 (3) , 557-566
- https://doi.org/10.1016/s0304-3959(02)00255-5
Abstract
A double-blind, randomised, placebo-controlled 8-week study was conducted to evaluate the efficacy and safety of gabapentin in the treatment of neuropathic pain, using doses up to 2400 mg/day. The study used a novel design that was symptom- rather than syndrome-based; an approach that aimedKeywords
This publication has 26 references indexed in Scilit:
- The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signsPAIN®, 2001
- Psychological Aspects of Neuropathic PainThe Clinical Journal of Pain, 2000
- Gabapentin as an Adjuvant to Opioid Analgesia for Neuropathic Cancer PainJournal of Pain and Symptom Management, 1999
- Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes MellitusA Randomized Controlled TrialJAMA, 1998
- Effects of Gabapentin on the Different Components of Peripheral and Central Neuropathic Pain Syndromes: A Pilot StudyEuropean Neurology, 1998
- Persistent Pain and Well-beingJAMA, 1998
- How Do Drugs Relieve Neurogenic Pain?Drugs & Aging, 1997
- Open label gabapentin treatment for pain in multiple sclerosisMultiple Sclerosis Journal, 1997
- Development and preliminary validation of a pain measure specific to neuropathic painNeurology, 1997
- Study of verbal description in neuropathic painPain, 1990